The Valley Desk

ArticleCrohn's & colitis 360Published

The Efficacy and Safety of Switching From Originator Infliximab to Single or Double Switch Biosimilar Among a Nationwide Cohort of Inflammatory Bowel Disease Patients

Read the publication ↗ Open access copy ↗

Regional connection

Verified Author affiliations on the Europe PMC record name Perelman School of Medicine, Philadelphia VA Medical Center, University of Pennsylvania. Affiliation source

Publication record

Type
Article
Venue
Crohn's & colitis 360
Published
Subject terms
Inflammatory Bowel Disease; Infliximab; Biosimilars; Double Switch; Inflectra; Renflexis; Single Switch
PubMed ID
36778941
PubMed Central ID
PMC9802034
Added to directory
Source checked

Report a correction or request removal